Tilbake til søkeresultatene

PROSBIO-Prosess- og biomedisinsk industri

New antifungal antibiotics produced by genetically engineered bacteria

Tildelt: kr 7,4 mill.

Prosjektnummer:

168352

Prosjektperiode:

2005 - 2008

Organisasjon:

Fagområder:

Samarbeidsland:

Fungal infections are on the rise, especially among HIV and cancer patients, as well as people subjected to organ transplantation. Polyene macrolide antibiotics are considered one of the best drugs for fighting invasive fungal infections. However, such ne gative properties of these antibiotics as toxicity and poor bioavailability create considerable problems in medical practice. We have recently cloned and characterised a set of genes for biosynthesis of antifungal polyene macrolide nystatin, and shown tha t novel nystatin analogues with improved properties can be produced through manipulation of these genes. World-wide patent application on the nystatin genes and their manipulation and utility has been filed, and a start-up biotech company Biosergen AS is being established in Trondheim as a joint venture of SINVENT AS (Norway) and Karolinska Innovations AB (Sweden). The major goal of Biosergen AS will be to use nystatin technology, i.e. manipulation of the nystatin biosynthetic genes, for production of dru g candidates for treatment of invasive fungal infections. Challenging problems of increasing the yields of these compounds produced by genetically engineered bacteria, as well as their purification will be addressed in this project. Purified compounds wil l be tested for biological activity and toxicity in order to select lead compounds that can be further advanced into clinical trials.

Budsjettformål:

PROSBIO-Prosess- og biomedisinsk industri

Temaer og emner

Ingen temaer knyttet til prosjektet